| 1.67 -0.09 (-5.11%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.14 | 1-year : | 2.51 |
| Resists | First : | 1.83 | Second : | 2.14 |
| Pivot price | 1.59 |
|||
| Supports | First : | 1.55 | Second : | 1.37 |
| MAs | MA(5) : | 1.72 |
MA(20) : | 1.59 |
| MA(100) : | 1.45 |
MA(250) : | 1.38 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 72.4 |
D(3) : | 76.7 |
| RSI | RSI(14): 53.7 |
|||
| 52-week | High : | 2 | Low : | 1.03 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GERN ] has closed below upper band by 33.6%. Bollinger Bands are 50.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.79 - 1.8 | 1.8 - 1.8 |
| Low: | 1.64 - 1.65 | 1.65 - 1.66 |
| Close: | 1.65 - 1.67 | 1.67 - 1.68 |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Sun, 12 Apr 2026
Geron (GERN) 2025 revenue surges to $183.6M driven by RYTELO commercial success - MSN
Fri, 10 Apr 2026
GERN Stock Holds Tight Range As Traders Eye Next Move - timothysykes.com
Thu, 19 Mar 2026
Geron: Minimal Sales Growth But A Potential Run-Up Ahead (NASDAQ:GERN) - Seeking Alpha
Tue, 03 Mar 2026
Is Geron (GERN) Using Its New ATM Program To Prioritize Flexibility Over Shareholder Dilution? - Yahoo Finance
Mon, 23 Feb 2026
Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT - Yahoo Finance
Tue, 03 Feb 2026
Geron Corporation's (NASDAQ:GERN) Prospects Need A Boost To Lift Shares - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 641 (M) |
| Shares Float | 511 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 77.9 (%) |
| Shares Short | 63,220 (K) |
| Shares Short P.Month | 65,030 (K) |
| EPS | -0.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | -45.5 % |
| Operating Margin | -17.8 % |
| Return on Assets (ttm) | -5.6 % |
| Return on Equity (ttm) | -33 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 0.27 |
| Sales Per Share | 0.28 |
| EBITDA (p.s.) | -0.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -111 (M) |
| Levered Free Cash Flow | -78 (M) |
| PE Ratio | -12.85 |
| PEG Ratio | 0 |
| Price to Book value | 4.77 |
| Price to Sales | 5.81 |
| Price to Cash Flow | -9.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|